[On the pharmacotherapeutic treatment of cerebral palsy. 3. Pharmacotherapy of other defects and the neurological development].
D000109:Acetylcholine / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D002547:Cerebral Palsy / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D002746:Chlorpromazine / Q000627:therapeutic use; D006311:Hearing Disorders / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008615:Mephenesin / Q000627:therapeutic use; D009132:Muscles / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011343:Procaine / Q000627:therapeutic use; D011736:Pyridoxine / Q000627:therapeutic use; D013064:Speech Disorders; D013831:Thiamine / Q000627:therapeutic use; D014785:Vision, Ocular; D014805:Vitamin B 12 / Q000627:therapeutic use
D010276:Parasympatholytics; D010880:Piperidines; D011343:Procaine; D008615:Mephenesin; D001285:Atropine; D011736:Pyridoxine; D000109:Acetylcholine; D014805:Vitamin B 12; D002746:Chlorpromazine; D013831:Thiamine
Uber die pharmakotherapeutische Behandlung der cerebralen Kinderlähmung. 3. Die Pharmakotherapie sonstiger Defekte und ie neurologische Entwicklung.